DRMAW

Dermata Therapeutics, Inc., a biotechnology company in the clinical development stage, is headquartered in San Diego, California, and was established in 2014. The firm's core mission is to develop innovative treatments for a variety of dermatological and cosmetic skin conditions. Its flagship investigational product, DMT310, is a topical formula applied once weekly that is currently undergoing clinical trials. This primary compound is being evaluated for its effectiveness against acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. Additionally, the company is advancing DMT410, which is intended to address hyperhidrosis (excessive sweating) and other aesthetic concerns.